Core Viewpoint - Shanghai Shanshi Capital is set to become a significant strategic shareholder of MicroPort Medical, following its recent acquisition of Kanghua Biotech [2][3]. Group 1: Shareholder Changes - MicroPort Medical announced on July 25 that it received notice from Otsuka Medical Devices Co., Ltd. regarding the conditional sale of approximately 291 million shares, which will involve several buyers including Shanghai Shanshi Capital [2]. - The transaction is expected to enhance MicroPort Medical's strategic positioning, leveraging Shanshi Capital's state-owned background and industry resources for business expansion and potential strategic acquisitions [3]. Group 2: Investment Strategy - Shanghai Shanshi Capital, fully owned by Shanghai State-owned Assets Supervision and Administration Commission, focuses on investment opportunities in strategic emerging industries such as biomedicine and green environmental protection [3]. - The Shanghai Biomedicine Fund, initiated by Shanshi Group in December 2020, aims for a total management scale of 50 billion yuan, creating an innovative investment platform in the biomedicine sector [3]. Group 3: Company Overview - MicroPort Medical, established in 1998 and headquartered in Zhangjiang, Shanghai, is a leading innovative high-end medical device group in China [4]. Group 4: Market Performance - On July 25, MicroPort Medical's stock closed at HKD 10.94 per share, with a 4.59% increase, marking a 34% rise over the past three trading days, bringing its latest market capitalization to HKD 20.2 billion [7].
暴涨34%！上海国资，出手！